Catheter Precision (VTAK) Income from Non-Controlling Interests (2025 - 2026)
Catheter Precision (VTAK) reported Income from Non-Controlling Interests of -$9000.0 for Q1 2026, up 87.14% on a QoQ basis from -$70000.0 in Q4 2025.
Catheter Precision (VTAK) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$9000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$521000.0 (changed N/A YoY) and the FY2025 annual result came in at -$512000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests advanced to -$9000.0 in Q1 2026 per VTAK's latest filing, from -$70000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$9000.0 in Q1 2026 and bottomed at -$349000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -5.85 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 22.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 100,000.00 |
| 10 | Catheter Precision | 2.01 Mn | 1.20 Mn | 390,000.00 | -9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,000.00 |
| Dec 31, 2025 | -70,000.00 |
| Sep 30, 2025 | -93,000.00 |
| Jun 30, 2025 | -349,000.00 |